The article discusses the effectiveness of molecular imaging techniques, such as positron emission tomography (PET) and single photon emission computerized tomography (SPECT), in the identification of biomarkers for neuropsychiatric disorders (NPD). Accordingly, these techniques use radiolabeled tracers which allow direct investigation of neuroreceptors in vivo at any stage of the NPD. An example of such identification are the dopamine transporter (DAT) radiotracers that evaluate dopamine neuronal loss in Parkinson's disease (PD).